Find and Pitch Jounalists, Get Your Story Covered

Tags: addiction Artificial intelligence biotech Cancer CRISPR

	Profile	Recent Articles on Subject
1	Bob Herman STAT News Health care business reporter. Indiana Health carebusiness	STAT+: Aetna lawsuit alleges radiology group of fraudulent billing and abuse of federal arbitration - 4 days ago STAT+: A tough year for health insurance stocks as patients get more care - 9 days ago STAT+: How often ‘value-based care’ is uttered on Wall Street - 29 days ago STAT+: Former UnitedHealth doctors detail what changed at their clinics after takeovers - 3 months ago STAT+: Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows - 3 months ago STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - 3 months ago STAT+: UnitedHealth sues Medicare to reverse downgraded star ratings - 3 months ago STAT+: Private equity firms to acquire health care billing and payments firm R1 in $8.9 billion deal - 5 months ago STAT+: Why health care spending keeps climbing - 7 months ago
2	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	STAT stories you might have missed in 2024 - 5 days ago STAT+: Stump Pharmalot: An Ask Me Anything with Ed Silverman - 10 months ago STAT stories you might have missed in 2023 - about 1 year ago STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D - about 1 year ago An Ask Me Anything with STAT’s Nicholas St. Fleur - about 1 year ago
3	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal - 17 days ago STAT+: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program - 18 days ago STAT+: Up and down the ladder: The latest comings and goings - 18 days ago STAT+: Up and down the ladder: The latest comings and goings - 25 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: AstraZeneca says China has detained a senior executive - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago
4	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 19 days ago STAT+: Exact Sciences wins FDA approval for improved stool-based colon cancer test - 3 months ago STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present - 4 months ago STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending - 4 months ago
5	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success? - 19 days ago STAT+: The end of 23andMe’s drug discovery dream - about 2 months ago STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease - 7 months ago STAT+: Why Sanofi got shellacked - about 1 year ago
6	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - 23 days ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - 2 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 4 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 4 months ago STAT+: On Andrew Left and the government’s fraud case - 5 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 9 months ago STAT+: Weed for weight loss, and more from Biotech Land - 9 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 9 months ago STAT+: The biotech scorecard for the first quarter: 17 stock-moving events to watch - 12 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - about 1 year ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: ‘Significant talent shortage’ threatens the rise of radiopharmaceuticals - 30 days ago STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger - about 1 month ago STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance - 4 months ago STAT+: Tome Biosciences, once a high-flying gene-editing startup, is floundering - 4 months ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 7 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 9 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 10 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - 12 months ago
8	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	STAT+: Why the crowded market for ambient AI medical scribes might be ripe for consolidation - about 1 month ago
9	Tara Bannow STAT News Reporter @statnews. healthcarejournalism	STAT+: The dropped call that took down Centene’s Medicare Advantage star ratings - 2 months ago STAT+: For the behemoth UnitedHealth, a new threat to Medicare profits - 2 months ago STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers - 3 months ago STAT+: Humana cutting Medicare Advantage plans that cover 10% of members - 4 months ago STAT+: UnitedHealthcare’s latest contract dispute, this time with Trinity Health, leaves thousands out-of-network - 5 months ago
10	Casey Ross STAT News National health tech writer @statnews. Covers #AI, #digitalhealth. Cleveland, OH health technologyjournalismartificial intelligencedigital health	STAT+: For the behemoth UnitedHealth, a new threat to Medicare profits - 2 months ago STAT+: Medicare Advantage insurers ramped up use of technology to deny claims, Senate investigation shows - 3 months ago STAT+: AI in medicine: A national registry could help increase transparency, experts say - 4 months ago STAT Virtual Event: Putting AI to the Test - over 1 year ago

Journalists covering STAT+